Combining VSV with immune checkpoint inhibitors (such as anti-PD-1/PD-L1 or anti-CTLA-4 antibodies) may further alleviate immune suppression in the tumor microenvironment and enhance the activity of effector T cells. Here, CTLA4 is linked to neoplasm.